Methotrexate USP And EP Grade

Methotrexate USP And EP Grade

Synonyms 4-Amino-10-methylfolic acid hydrate; L-4-Amino-N10-methylpteroylglutamic acid hydrate; L-Amethopterin hydrate; Antifolan hydrate; MTX hydrate;Methotrexate hydrate; Methylaminopterin hydrate

CAS Number: 59-05-2 Molecular Formula: C20H22N8O5 Molecular Weight: 454.46

MDL Number: MFCD00150847

Configure Your Product:

SKU 02199855-CF
Price:
$25.30
In Stock
Request a quote
Description

Product Description

Methotrexate is a cell cycle arresting agent with varying effects. Methotrexate has been reported to arrest the cell cycle in late G1/S thus leading to the inhibition of the synthesis of DNA, RNA, thymidylates, and proteins. The main mechanism of action is reported to involve the inhibition of enzymes involved in purine metabolism which leads to the accumulation of adenosine or the suppression of intercellular adhesion molecule expression by T cells. Additionally, this compound has been observed to inhibit DHFR.

Application Notes

Methotrexate is used for chemotherapy either alone or in combination with other agents. It is effective for the treatment of a number of cancers including: breast, head and neck, leukemia, lymphoma, lung, osteosarcoma, bladder, and trophoblastic neoplasms. It is also used in treatment of autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. It is used to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites.

Usage Statement

Research Use Only (RUO). Ready for CE IVD labeling of clinical applications.

Key Applications

Chemotherapy

Specifications
SKU 02199855-CF
Alternate Names 4-Amino-10-methylfolic acid hydrate; L-4-Amino-N10-methylpteroylglutamic acid hydrate; L-Amethopterin hydrate; Antifolan hydrate; MTX hydrate;Methotrexate hydrate; Methylaminopterin hydrate
Application Notes Methotrexate is used for chemotherapy either alone or in combination with other agents. It is effective for the treatment of a number of cancers including: breast, head and neck, leukemia, lymphoma, lung, osteosarcoma, bladder, and trophoblastic neoplasms. It is also used in treatment of autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions. It is used to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites.
Biochemical Physiological Actions Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis.
Chemical Class Pharmaceuticals
Grade USP and EP Grade
Hazard Statements H301-H315-H319-H360
Heavy Metals ≤50 ppm
Applications Chemotherapy
MDL # MFCD00150847
Molecular Formula C20H22N8O5
Molecular Weight 454.46
Optical Rotation +19° to +24° (anhydrous basis)
Personal Protective Equipment Eyeshields, Faceshields, full-face particle respirator, Gloves, respirator cartridge, respirator filter
Physical Appearance Yellow to Orange Powder
Residue on Ignition ≤0.1%
RTECS Number MA1225000
Safety Symbol GHS06, GHS08
Solubility Practically insoluble in water, ethanol, chloroform and diethyl ether; freely soluble in dilute solutions of alkaline hydroxides and carbonates; soluble in dilute hydrochloric acid.
Storage and Handling Store at + 4 °C. Protect from light.
Sulphated Ash ≤0.1%
Usage Statement Research Use Only (RUO). Ready for CE IVD labeling of clinical applications.